Recursion Pharmaceuticals, Inc.

Artificial intelligence was more than a buzzword in 2024; it shaped pharmaceutical industry investments throughout the year, with multiple billion-dollar partnerships and acquisitions across the drug

Najat Khan has built her career at the intersection of drug development and technological innovation. As chief R&D and commercial officer at Recursion, she is helping to scale one of biotech’s (or

Financing of UK biotech companies nearly doubled in 2024 compared with the year before, with £3.5bn ($4.34bn) being raised to support new and existing companies. That represented a 94% increase in tot

Pharma executives no longer ask whether AI is important in their industry – that much is certain, and it is already ubiquitous. As Lamine Mbow , global head of discovery research at Boehringer Ingelh